Technology | May 21, 2018

Innovative Health Receives FDA Clearance to Reprocess the ViewFlex Xtra Diagnostic Ultrasound Catheter

Company reprocesses devices with more complex technology, addressing the unmet need

The Abbott ViewFlex Xtra Diagnostic Ultrasound Catheter now can be reprocessed by Innovative Health.

May 21, 2018 — Cardiology medical device reprocessing company Innovative Health recently received U.S. Food and Drug Administration (FDA) clearance to reprocess the Abbott ViewFlex Xtra Diagnostic Ultrasound Catheter. Ultimately, this clearance will allow the company to develop a full product suite for clinicians based on this new category of devices, including other widely used mapping and imaging catheters.

The company said it launched this product reprocessing effort based on direct feedback from its customers, including clinicians in the electrophysiology (EP) field.The device is much more complex to reprocess than many types of catheters, which required the FDA clearance. 

Innovative Health continues to make extensive investments in research and development, enabling the company to pursue clearances for devices which are based on the very latest, difficult-to-reprocess technologies. In the last two years, the company has received three times more EP FDA clearances than all of its competitors combined. Reprocessors must actively pursue FDA clearances in order to introduce new products, which involves documenting that they can achieve levels of quality and safety comparable to those of the original device. This research can also help companies like Innovative Health identify entirely new reprocessing approaches, as it has with the ViewFlex catheter, allowing them to more easily pursue clearances for other new products based on similar technologies.

The ViewFlex catheter is used frequently in EP labs today to help visualize cardiac anatomy and physiology. With this recent FDA clearance, it will be added to Innovative Health’s vast portfolio of reprocessed devices include diagnostic, ultrasound and mapping catheters, as well as other EP-specific devices. Innovative Health partners with hospitals to collect the devices, then applies a rigorous, proprietary process to clean, test and sterilize them for re-use. As a result, the company claims it can help hospitals save hundreds of thousands of dollars on medical device spending per year, all while maintaining patient safety.

For more information: innovative-health.com

 

Related Content

Results of the STROKE-VT trial showed direct oral anticoagulants (DOACs) are more effective than aspirin in reducing cerebrovascular events, including stroke in patients undergoing ventricular tachycardia ablation.

Results of the STROKE-VT trial showed direct oral anticoagulants (DOACs) are more effective than aspirin in reducing cerebrovascular events, including stroke in patients undergoing ventricular tachycardia ablation.

News | EP Lab | July 29, 2021
July 29, 2021 – Results of the STROKE-VT tr...
The devices compared in the study were the Bardy Carnation Ambulatory Monitor long-term continuous ECG system (left) and the BioGuardian MCT cardiac event monitor (right).  #HRS21 #HRS2021 #HeartRhythm21

The devices compared in the study were the Bardy Carnation Ambulatory Monitor long-term continuous ECG system (left) and the BioGuardian MCT cardiac event monitor (right). 

News | EP Lab | July 29, 2021
July 29, 2021 – Results from a new clinical trial find human-oversight dependent continuous electrocardiography (ECG)
St. Jude Medical Pays $27 Million for Allegedly Selling Defective ICD and CRT-D devices
News | EP Lab | July 28, 2021
July 28, 2021 — The U.S. Justice Department announced earlier this month that St. Jude Medical Inc.
Heart Rhythm Society, HRS, 2021 Late-Breaking Clinical Trials in Electrophysiology. #HRS #HRS2021 #HRS21 #Heartrhythm21
Feature | EP Lab | July 28, 2021
July 28, 2021 — Here is the complete list of late-breaking clinical trials (LBCT) and links to articles on all of the
The AcQMap 3D Imaging and Mapping System, left, and the AliveCor KardiaMobile device and app for personal ECG monitoring using a smartphone, right. The companies plan to use remote monitoring to see if it helps improve care for ablation patients.

The AcQMap 3D Imaging and Mapping System, left, and the AliveCor KardiaMobile device and app for personal ECG monitoring using a smartphone, right. The companies plan to use remote monitoring to see if it helps improve care for ablation patients.

News | EP Lab | July 27, 2021
July 27, 2021 — AliveCor Inc., which offers FDA-cleared, smart-phone enabled personal electrocardiogram (ECG) technol
Medtronic announced new data from the landmark WRAP-IT study published in Heart Rhythm,[1] demonstrating a significantly lower infection risk for patients who develop hematomas after cardiac implantable electronic devices (CIEDs) when the Tyrx Absorbable Antibacterial Envelope is used at implant. The analysis showed an 82% reduction in major CIED infections among patients with the Tyrx Envelope who developed hematomas compared to patients in the control group who developed hematomas.
News | EP Lab | July 27, 2021
July 27, 2021 — Medtronic announced new data from the landmark WRAP-IT study...
Implicity provides a remote cardiac monitoring and research platform used by Independent Diagnostic Testing Facilities and medical centers to deliver high-quality care for patients with connected cardiac devices. On this platform, Implicity aggregates, normalizes and standardizes data from any implantable cardiac device across all manufacturers.

Implicity provides a remote cardiac monitoring and research platform used by Independent Diagnostic Testing Facilities and medical centers to deliver high-quality care for patients with connected cardiac devices. On this platform, Implicity aggregates, normalizes and standardizes data from any implantable cardiac device across all manufacturers.

News | EP Lab | June 02, 2021
June 2, 2021 — Implicity, a leader in remote patient monitoring software and cardiac data management solutions, annou
Left, the AcQCross Transseptal Crossing Device offers versatility to be utilized with top sheaths currently used in left atrium EP and structural heart procedures. Right, the AcQMap next-generation mapping catheter integrates high-resolution ultrasound-based imaging and non-contact mapping catheter with improved torque response, handling and maneuverability.

Left, the AcQCross Transseptal Crossing Device offers versatility to be utilized with top sheaths currently used in left atrium EP and structural heart procedures. Right, the AcQMap next-generation mapping catheter integrates high-resolution ultrasound-based imaging and non-contact mapping catheter with improved torque response, handling and maneuverability.

News | EP Lab | May 25, 2021
May 25, 2021 — Acutus Medical Inc.
Etripamil nasal spray was shown in a post-hoc analysis to resolve paroxysmal supraventricular tachycardia faster and more completely than placebo in most patients and reduced the number of emergency room visits for additional interventions. 

Etripamil nasal spray was shown in a post-hoc analysis to resolve paroxysmal supraventricular tachycardia faster and more completely than placebo in most patients and reduced the number of emergency room visits for additional interventions. 

Feature | EP Lab | May 16, 2021 | By Dave Fornell, Editor
May 16, 2020 — New data from in the ...
A device programmer showing the suspension of ICD therapies (orange bar, red arrow) with iPhone 12 laying over patient’s chest (green arrow) and fluoroscopy of iPhone 12 showing the circular magnet array (yellow arrow). Image from a small study at Henry Ford Hospital. Read the full study

A device programmer showing the suspension of ICD therapies (orange bar, red arrow) with iPhone 12 laying over patient’s chest (green arrow) and fluoroscopy of iPhone 12 showing the circular magnet array (yellow arrow). Image from a small study at Henry Ford Hospital. Read the full study

News | EP Lab | May 14, 2021
May 14, 2021 — The U.S.